Microenvironmental regulation of tumour angiogenesis

By M. D. Palma, D. Biziato, T. Petrova. Nature Reviews. Cancer, 2017

1,605 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments (2023, background): “A thorough review has concluded the role of CAFs and extracellular components generated from CAFs in tumor angiogenesis [410].”
Targeting Tumor Microenvironment for Cancer Therapy (2019, background): “One example is the phase 1 trial NCT02665416 that evaluates the combination of Selicrelumab, a CD40 agonist, with Vanucizumab, a bispecific antibody that targets simultaneously ANGPT2 and VEGF-A versus the action of Selicrelumab with Bevacizumab, an anti-VEGF antibody, for treatment of advanced soli”
Three-Dimensional in Vitro Cell Culture Models in Drug Discovery and Drug Repositioning (2018, background): “…and bone marrow-derived cells, a process that cannot only be exploited for cancer therapy but for which the stromal environment is an important factor in regulating drug response (Crawford and Ferrara, 2009; Egeblad et al., 2010; Gacche, 2015; Lopes-Bastos et al., 2016; De Palma et al., 2017).”